Abstract
Blood monocytes which differentiate into tissue macrophages, are unique in that they can not only initiate immune responses but can also be effector cells which contribute to the resolution of these responses. There is no single activation phenotype, and macrophages can be induced to differentiate into cells that either exacerbate or inhibit acute inflammation. Similarly, these cells can promote, deviate or suppress adaptive immune responses. This review focuses on the mechanisms that have been implicated in the recruitment, activation and differentiation of inflammatory monocytes / macrophages in chronic inflammatory bowel diseases, i.e. ulcerative colitis and Crohns disease. These mechanisms might provide attractive targets for novel therapies.
Keywords: inflammatory bowel disease, crohns disease, ulcerative colitis, monocyte, macrophage
Current Drug Targets - Inflammation & Allergy
Title: Macrophages in Inflammatory Bowel Disease
Volume: 2 Issue: 2
Author(s): Olof Grip, Sabina Janciauskiene and Stefan Lindgren
Affiliation:
Keywords: inflammatory bowel disease, crohns disease, ulcerative colitis, monocyte, macrophage
Abstract: Blood monocytes which differentiate into tissue macrophages, are unique in that they can not only initiate immune responses but can also be effector cells which contribute to the resolution of these responses. There is no single activation phenotype, and macrophages can be induced to differentiate into cells that either exacerbate or inhibit acute inflammation. Similarly, these cells can promote, deviate or suppress adaptive immune responses. This review focuses on the mechanisms that have been implicated in the recruitment, activation and differentiation of inflammatory monocytes / macrophages in chronic inflammatory bowel diseases, i.e. ulcerative colitis and Crohns disease. These mechanisms might provide attractive targets for novel therapies.
Export Options
About this article
Cite this article as:
Grip Olof, Janciauskiene Sabina and Lindgren Stefan, Macrophages in Inflammatory Bowel Disease, Current Drug Targets - Inflammation & Allergy 2003; 2 (2) . https://dx.doi.org/10.2174/1568010033484179
DOI https://dx.doi.org/10.2174/1568010033484179 |
Print ISSN 1568-010X |
Publisher Name Bentham Science Publisher |
Online ISSN 1568-010X |
Related Articles
-
Color Doppler Ultrasound Assessment of Clinical Activity in Inflammatory Bowel Disease
Current Medical Imaging Signaling Pathways Associated with Inflammatory Bowel Disease
Recent Patents on Inflammation & Allergy Drug Discovery Cardiovascular Manifestations in Inflammatory Bowel Disease
Current Cardiology Reviews Desirability Based Optimization of New Mesalazine Modified Release Formulations: Compression Coated Tablets and Mini Tablets in Capsules
Letters in Drug Design & Discovery Signaling Molecules: The Pathogenic Role of the IL-6/STAT-3 Trans Signaling Pathway in Intestinal Inflammation and in Colonic Cancer
Current Drug Targets Commonalities and Differences Between Crohns Disease and Ulcerative Colitis: The Genetic Clues to their Interpretation
Inflammation & Allergy - Drug Targets (Discontinued) Genetics and Ulcerative Colitis: What are the Clinical Implications?
Current Drug Targets Probiotic Lactobacilli: A New Perspective for the Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Design Neuropeptide - Adipose Tissue Communication and Intestinal Pathophysiology
Current Pharmaceutical Design Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?
Current Clinical Pharmacology Cytokine Therapies in Crohns Disease: Where are We Now and where should We Go?
Inflammation & Allergy - Drug Targets (Discontinued) Use of Mesenchymal Stem Cells in Crohn's Disease and Perianal Fistulas: A Narrative Review
Current Stem Cell Research & Therapy Modeling Inflammatory Bowel Disease by Intestinal Organoids
Recent Advances in Inflammation & Allergy Drug Discovery Use of Synbiotics for Ulcerative Colitis Treatment
Current Clinical Pharmacology Alternative Therapy in the Prevention of Experimental and Clinical Inflammatory Bowel Disease. Impact of Regular Physical Activity, Intestinal Alkaline Phosphatase and Herbal Products
Current Pharmaceutical Design NLRP3: A Promising Therapeutic Target for Inflammatory Bowel Disease
Current Drug Targets Dissecting the Mechanisms of Intestinal Immune Homeostasis by Analyzing T-Cell Immune Response in Crohn's Disease and Colorectal Cancer
Current Gene Therapy Epigenetic Modifications of the Nuclear Factor Kappa B Signalling Pathway and its Impact on Inflammatory Bowel Disease
Current Pharmaceutical Design Immunomodulatory Activity of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Randomized Controlled Trials in Prevention of PostSurgical Recurrence in Crohn’s Disease
Reviews on Recent Clinical Trials